Topera Medical

Shane Brown Promoted to President of GT Medical Technologies, Inc.

Retrieved on: 
Thursday, June 29, 2023
Brain, Marketing, Abbott, Research, CCO, Hospital, Patient, Itamar Medical, Topera Medical, St. Jude Medical, Nursing, Medical imaging

Since joining GT Medical Technologies, Inc. in May 2022, Mr. Brown has served as the Chief Commercial Officer, responsible for leading sales, marketing, customer operations and human resources.

Key Points: 
  • Since joining GT Medical Technologies, Inc. in May 2022, Mr. Brown has served as the Chief Commercial Officer, responsible for leading sales, marketing, customer operations and human resources.
  • We have the opportunity to drive adoption of this amazing therapy for patients with brain tumors who need better options," said Shane Brown, president of GT Medical Technologies.
  • Before joining GT Medical Technologies, Mr. Brown was the president and general manager of North America for Itamar Medical, a NASDAQ-listed company that was acquired by ZOLL Medical in December 2021.
  • Previously, Mr. Brown has held leadership roles in a host of other medical device companies including AngioDynamics, AGA Medical, St. Jude Medical, Topera and Abbott.

Moxe Health Raises $30M Series B to Further Advance Interoperability

Retrieved on: 
Wednesday, June 1, 2022
Data Management, Health, Security, Technology, Practice Management, Software, Networks, PSC, Chief executive officer, CEO, Piper Sandler Companies, API, Investment, Johns Hopkins University, Risk, Technology, NYSE, Apollo, Wilson, Pete Musser, History, Cameron Health, Laika (EHR testing framework), Data science, Healthcare, Health insurance, Spektr-RG, Topera Medical

Moxe will use this funding to prioritize team expansion and technology investments to further advance its clinical data exchange solutions.

Key Points: 
  • Moxe will use this funding to prioritize team expansion and technology investments to further advance its clinical data exchange solutions.
  • By unlocking clinical data, Moxe enables smarter collaboration between healthcare stakeholders and streamlines payment and operational workflows.
  • Moxe eliminates administrative waste by evolving patient-centric interoperability and improving payer-provider collaboration, said Dan Wilson, founder and CEO of Moxe Health.
  • This funding emphasizes our confidence in the Moxe team and our strong belief in the company as a proven interoperability leader.

Shane H. Brown Joins GT Medical Technologies as Chief Commercial Officer

Retrieved on: 
Thursday, May 26, 2022
Brain, Radiation, Cancer, St. Jude Medical, Patient, NASDAQ, CCO, Palm Springs (2020 film), Marketing, FDA, Malignancy, Glioblastoma, Miami University, Standard of care, GT, Topera Medical, Adoption, LinkedIn, Twitter, Fortune 500, Growth, Abbott, Management, Medical imaging

TEMPE, Ariz., May 26, 2022 /PRNewswire/ -- Shane Brown has joined GT Medical Technologies as its chief commercial officer. In this role, he will oversee all aspects of the company's commercial strategies to drive growth and adoption of GammaTile Therapy. 

Key Points: 
  • Shane Brown will join the executive team, leading the commercial organization to accelerate the growth of GammaTile Therapy in the U.S. market
    TEMPE, Ariz., May 26, 2022 /PRNewswire/ -- Shane Brown has joined GT Medical Technologies as its chief commercial officer.
  • Shane Brown joined GT Medical Technologies as CCO to oversee the commercial strategies of GammaTile Therapy.
  • "We are pleased to welcome Shane Brown to the leadership team in the role of chief commercial officer," said GT Medical Technologies President and CEO Matthew E. Likens.
  • Before joining GT Medical Technologies, Mr. Brown was the president and general manager of North America for Itamar Medical, a NASDAQ-listed company that ZOLL Medical acquired for $538 million in December 2021.

BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology

Retrieved on: 
Wednesday, June 30, 2021
Branches of biology, Medicine, Cardiac electrophysiology, Arrhythmia, Heart, Catheter ablation, Clinical medicine, Medical devices, Biomedical engineering, Clinical cardiac electrophysiology, Topera Medical

BioSigs non-invasive computerized technology, the PURE EP(tm) System, aims to drive procedural efficiency and efficacy in electrophysiology.

Key Points: 
  • BioSigs non-invasive computerized technology, the PURE EP(tm) System, aims to drive procedural efficiency and efficacy in electrophysiology.
  • The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.
  • Previously the Company increased the patient case goal from 1000 to at least 1500 procedures by the end of 2021, having delivered 425 procedures at the end of 2020.
  • The Company is currently conducting patient cases in nine medical centers across the country.

Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System

Retrieved on: 
Thursday, May 27, 2021
Catheter ablation, Circulatory system, Cardiac arrhythmia, Clinical medicine, Cardiovascular system, Atrial fibrillation, Arrhythmia, Heart, Ablation, Sensei robotic catheter system, Topera Medical

CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.

Key Points: 
  • CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.
  • In contrast to most contemporary ablation systems, the AcQBlate Force Catheter and System can operate both in a stand-alone manner or in conjunction with compatible 3D mapping systems.
  • The new ablation system is comprised of Acutus AcQBlate Force Catheter and Qubic Force module and seamlessly integrates with the Qubic RF generator and Qiona irrigation pump.
  • Ariyarathna N. et al., Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias: Evolution or History Repeating Itself?

BioSig Technologies, Inc. Invited to Present at Wall Street Conference

Retrieved on: 
Monday, May 3, 2021
Cardiac arrhythmia, Arrhythmia, Atrial fibrillation, Catheter ablation, Fibrillation, Clinical medicine, Branches of biology, Medicine, Topera Medical, Clinical cardiac electrophysiology

The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.\nOne in 18 Americans suffers from cardiac arrhythmia.

Key Points: 
  • The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.\nOne in 18 Americans suffers from cardiac arrhythmia.
  • Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S.
  • Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
  • Investors and security holders are urged to read these documents free of charge on the SEC\'s website at http://www.sec.gov.

Kardium Announces $115M in New Financing for Innovative Atrial Fibrillation Treatment

Retrieved on: 
Monday, January 25, 2021
Biotechnology, Health, Medical devices, Cardiac arrhythmia, Circulatory system, Cardiovascular system, Cardiology, Atrial fibrillation, Fibrillation, Topera Medical, Michel Haïssaguerre

Kardium Inc. , developer of the Globe Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round.

Key Points: 
  • Kardium Inc. , developer of the Globe Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round.
  • We are tremendously excited to have Fidelity Management & Research Company join Kardium as a major investor, along with the T. Rowe Price funds, said Kevin Chaplin, CEO of Kardium.
  • Kardium was founded in 2007, with the vision of providing a complete solution for the treatment of the worlds most common heart rhythm disorder, atrial fibrillation.
  • Kardium Inc. ( kardium.com ) is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation: the Globe Mapping and Ablation System.

Kardium Marks First Commercial Procedures of Globe® Mapping and Ablation System

Retrieved on: 
Tuesday, September 8, 2020
Cardiology, Software, Medical Supplies, Surgery, Health, Medical devices, Technology, Other Technology, Plasma physics, Cardiovascular system, Circulatory system, Clinical medicine, Ablation, Atrial fibrillation, Interventional radiology, Cardiac electrophysiology, Topera Medical, Sensei robotic catheter system

Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System .

Key Points: 
  • Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System .
  • View the full release here: https://www.businesswire.com/news/home/20200908005275/en/
    From right to left: Prof. Hans Kottkamp (Sana Hospital Benrath in Dsseldorf), Ashkan Sardari (Project Manager, Kardium), and Nele Thoms (Field Clinical Specialist, Kardium) during the first commercial procedure with the Globe Mapping and Ablation System.
  • Approval of the Globe System was based on the positive results from the GLOBAL-AF study , a multi-centre study that demonstrated the safety and effectiveness of the Globe Mapping and Ablation System.
  • Kardium Inc. ( kardium.com ) is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation: the Globe Mapping and Ablation System.

Kardium Receives CE Mark for Globe® Mapping and Ablation System

Retrieved on: 
Tuesday, June 30, 2020
Medical Supplies, Health, Medical devices, Technology, Surgery, Software, Cardiology, Medicine, Medical specialties, Circulatory system, Cardiac arrhythmia, RTT, Cardiology, Atrial fibrillation, Ablation, Cardiac electrophysiology, Sensei robotic catheter system, Topera Medical

Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System the most complete solution for the treatment of atrial fibrillation (AF).

Key Points: 
  • Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System the most complete solution for the treatment of atrial fibrillation (AF).
  • View the full release here: https://www.businesswire.com/news/home/20200630005232/en/
    The Globe mapping and ablation catheter from Kardium.
  • The CE mark approval was based on the positive results from the GLOBAL-AF study , a multi-centre study that demonstrated the safety and effectiveness of the Globe Mapping and Ablation System.
  • Kardium Inc. ( kardium.com ) is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation: the Globe Mapping and Ablation System.

Global Cardiac Mapping Market is Projected to Grow at a CAGR of 8.7% During the Forecast Period, 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 27, 2020
Health, Cardiology, Cardiac arrhythmia, Circulatory system, Cardiovascular system, Cardiology, Medical specialties, RTT, Atrial fibrillation, Atrial flutter, Topera Medical

The "Cardiac Mapping Market by Product (Contact Mapping Systems (Electroanatomical Mapping, Basket Catheter Mapping), Non-contact Mapping Systems), Indication (Atrial Fibrillation, Atrial Flutter, AVNRT), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Mapping Market by Product (Contact Mapping Systems (Electroanatomical Mapping, Basket Catheter Mapping), Non-contact Mapping Systems), Indication (Atrial Fibrillation, Atrial Flutter, AVNRT), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The contact cardiac mapping segment is projected to dominate the cardiac mapping products market during the forecast period.
  • The cardiac mapping products market has been segmented into contact with cardiac mapping systems and non-contact cardiac mapping systems.
  • The contact cardiac mapping systems segment further includes electroanatomical mapping, basket catheter mapping, and traditional endocardial mapping.